| Auranofin |
NCT02176135 |
Withdrawn |
Phase 1|Phase 2 |
Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection |
HIV |
https://ClinicalTrials.gov/show/NCT02176135 |
| Auranofin |
NCT02089048 |
Completed |
Phase 1 |
Auranofin PK Following Oral Dose Administration |
Amoebiasis |
https://ClinicalTrials.gov/show/NCT02089048 |
| Auranofin |
NCT01747798 |
Completed |
Early Phase 1 |
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT01747798 |
| Auranofin |
NCT01419691 |
Completed |
Phase 2 |
Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) |
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma|Leukemia, Prolymphocytic |
https://ClinicalTrials.gov/show/NCT01419691 |
| Auranofin |
NCT03456700 |
Active, not recruiting |
Phase 2 |
Auranofin and Sirolimus in Treating Participants With Ovarian Cancer |
Ovarian Serous Tumor|Recurrent Ovarian Carcinoma |
https://ClinicalTrials.gov/show/NCT03456700 |
| Auranofin |
NCT02736968 |
Recruiting |
Phase 2 |
Auranofin for Giardia Protozoa |
Amoebic Dysentery|Giardiasis |
https://ClinicalTrials.gov/show/NCT02736968 |
| Auranofin |
NCT02063698 |
Completed |
Phase 2 |
Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome |
Pain |
https://ClinicalTrials.gov/show/NCT02063698 |
| Auranofin |
NCT02126527 |
Withdrawn |
Phase 1 |
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer |
Recurrent Non-small Cell Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
https://ClinicalTrials.gov/show/NCT02126527 |
| Auranofin |
NCT01737502 |
Recruiting |
Phase 1|Phase 2 |
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer |
Extensive Stage Small Cell Lung Carcinoma|Lung Adenocarcinoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Small Cell Lung Carcinoma|Squamous Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer |
https://ClinicalTrials.gov/show/NCT01737502 |
| Auranofin |
NCT02961829 |
Active, not recruiting |
Not Applicable |
Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure |
Chronic Infection|HIV |
https://ClinicalTrials.gov/show/NCT02961829 |
| Auranofin |
NCT02968927 |
Active, not recruiting |
Phase 2 |
TB Host Directed Therapy |
Tuberculosis |
https://ClinicalTrials.gov/show/NCT02968927 |
| Auranofin |
NCT02770378 |
Active, not recruiting |
Phase 1|Phase 2 |
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma |
Glioblastoma |
https://ClinicalTrials.gov/show/NCT02770378 |
| Auranofin |
NCT03975790 |
Completed |
N/A |
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX |
Rheumatoid Arthritis |
https://ClinicalTrials.gov/show/NCT03975790 |
| Auranofin |
NCT01557348 |
Completed |
N/A |
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor |
Rheumatoid Arthritis |
https://ClinicalTrials.gov/show/NCT01557348 |
